Inflammation and sarcopenia: A systematic review and meta-analysis.
By G. Bano, C. Trevisan, S. Carraro, M. Solmi, C. Luchini, Brendon Stubbs, E. Manzato, G. Sergi, N. Veronese. Maturitas, 2017
673 citations recorded by the source corpus.
Inflammatory cytokines have been shown to prompt muscle wasting, ultimately stimulating protein catabolism and suppressing muscle synthesis. However, the possible association between inflammatory parameters and sarcopenia is poorly understood. We therefore aimed to summarize the current evidence about this topic with a meta-analysis of studies reporting serum inflammatory parameters in patients with sarcopenia vs. people without sarcopenia (controls). An electronic PubMed and Scopus search through to 09/01/2016 and meta-analysis of cross-sectional studies comparing serum levels of inflammatory cytokines between patients with sarcopenia and controls was made, calculating random-effects standardized mean differences (SMDs) ±95% confidence intervals (CIs) as the effect size. Out of 1370 initial hits, 17 studies with a total of 11249 participants (3072 with sarcopenia and 8177 without) were meta-analyzed. Sarcopenic participants had significantly higher levels of CRP (SMD=0.51; 95%CI 0.26, 0.77; p<0.0001; I2=96%) than controls. Conversely, serum IL6 levels were not significantly different (SMD=0.35; 95%CI: -0.19, 0.89; p=0.21; I2=97%) in people with sarcopenia versus controls. Sarcopenic people did not have higher levels of TNF-α than controls (SMD=0.28; 95%CI -0.26, 0.83; p=0.31; I2=97%). In conclusion, sarcopenia seems to be associated with elevated serum CRP levels; future longitudinal studies are needed to clarify this relationship.
Subfields: Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/96738196b6b5f084ba0ae157716302bdcd5adb74
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
Citations in the corpus
- Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. (2023, background): “There were differences in inflammation [52], clinical biomarkers [53], blood 25-hydroxyvitamin D [54], adiponectin [55], and pulse wave velocity [56] between sarcopenic patients and non-sarcopenic individuals.”